熊去氧胆酸

(重定向自膽烷酸

熊去氧胆酸(英語:Ursodeoxycholic acid,也被称为3α,7β-二羟基-5β-胆烷-24-羧酸,3α,7β-dihydroxy-5β-cholan-24-oic acid,缩写 UDCA),是一种来自熊膽胆汁酸[1],为次级胆汁酸,由初级胆汁酸经由细菌代谢生成。

Ursodeoxycholic acid
臨床資料
商品名英语Drug nomenclatureActigall
其他名稱ursodeoxycholic acid, Actigall, Ursosan, Urso, Urso Forte
AHFS/Drugs.comMonograph
MedlinePlusa699047
核准狀況
懷孕分級
给药途径oral
ATC碼
法律規範狀態
法律規範
识别信息
  • 3α,7β-dihydroxy-5β-cholan-24-oic acid
    OR
    (R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-
    10,13-dimethylhexadecahydro-
    1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
CAS号128-13-2  checkY
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB配體ID
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.004.437 編輯維基數據鏈接
化学信息
化学式C24H40O4
摩尔质量392.56 g/mol
3D模型(JSmol英语JSmol
熔点203 °C(397 °F)
  • O=C(O)CC[C@H]([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]4[C@H]2[C@@H](O)C[C@@H]3C[C@H](O)CC[C@@]34C)C
  • InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1 checkY
  • Key:RUDATBOHQWOJDD-UZVSRGJWSA-N checkY

它可以降低细胞表面ACE2受体的表达量。[2]

歷史

熊胆是熊去氧胆酸的天然来源。1955年,日本科学家成功化学合成了熊去氧胆酸[3]。1987年12月,艾尔建申請的熊去氧胆酸獲准在美國上市。[4]

参考文献

  1. ^ 放過熊吧!可治療膽結石的熊膽早就能用化學合成. 食力 foodNEXT. [2021-12-08]. (原始内容存档于2021-12-08) (中文(臺灣)). 
  2. ^ Teresa Brevini, Mailis Maes, Gwilym J. Webb, Binu V. John, Claudia D. Fuchs, Gustav Buescher, Lu Wang, Chelsea Griffiths, Marnie L. Brown, William E. Scott, Pehuén Pereyra-Gerber, William T. H. Gelson, Stephanie Brown, Scott Dillon, Daniele Muraro, Jo Sharp, Megan Neary, Helen Box, Lee Tatham, James Stewart, Paul Curley, Henry Pertinez, Sally Forrest, Petra Mlcochova, Sagar S. Varankar, Mahnaz Darvish-Damavandi, Victoria L. Mulcahy, Rhoda E. Kuc, Thomas L. Williams, James A. Heslop, Davide Rossetti, Olivia C. Tysoe, Vasileios Galanakis, Marta Vila-Gonzalez, Thomas W. M. Crozier, Johannes Bargehr, Sanjay Sinha, Sara S. Upponi, Corrina Fear, Lisa Swift, Kourosh Saeb-Parsy, Susan E. Davies, Axel Wester, Hannes Hagström, Espen Melum, Darran Clements, Peter Humphreys, Jo Herriott, Edyta Kijak, Helen Cox, Chloe Bramwell, Anthony Valentijn, Christopher J. R. Illingworth, UK-PBC research consortium, Bassam Dahman, Dustin R. Bastaich, Raphaella D. Ferreira, Thomas Marjot, Eleanor Barnes, Andrew M. Moon, Alfred S. Barritt, Ravindra K. Gupta, Stephen Baker, Anthony P. Davenport, Gareth Corbett, Vassilis G. Gorgoulis, Simon J. A. Buczacki, Joo-Hyeon Lee, Nicholas J. Matheson, Michael Trauner, Andrew J. Fisher, Paul Gibbs, Andrew J. Butler, Christopher J. E. Watson, George F. Mells, Gordon Dougan, Andrew Owen, Ansgar W. Lohse, Ludovic Vallier, Fotios Sampaziotis. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022-12-05 [2022-12-07]. ISSN 0028-0836. doi:10.1038/s41586-022-05594-0. (原始内容存档于2023-06-26) (英语). 
  3. ^ Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal use and animal protection. Journal of Ethnobiology and Ethnomedicine. 2009, 5 (1): 2. PMC 2630947 . PMID 19138420. doi:10.1186/1746-4269-5-2. 
  4. ^ Actigall: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [29 April 2020]. (原始内容存档于2020-10-19). 

外部链接